Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
BIOCON ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-23 |
ADCOCK INGRAM Jun-14 |
BIOCON / ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 388 | 319 | - | |
Low | Rs | 192 | 230 | - | |
Sales per share (Unadj.) | Rs | 93.1 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 5.4 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 14.6 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 146.5 | 74.5 | - | |
Shares outstanding (eoy) | m | 1,200.60 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.1 | 2.9 | 107.6% | |
Avg P/E ratio | x | 54.1 | -11.5 | -471.1% | |
P/CF ratio (eoy) | x | 19.8 | -13.9 | -142.9% | |
Price / Book Value ratio | x | 2.0 | 3.7 | 53.6% | |
Dividend payout | % | 28.0 | 0 | - | |
Avg Mkt Cap | Rs m | 347,814 | 46,340 | 750.6% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 21,810 | 2,908 | 749.9% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 111,742 | 16,016 | 697.7% | |
Other income | Rs m | 7,681 | 112 | 6,848.5% | |
Total revenues | Rs m | 119,423 | 16,128 | 740.5% | |
Gross profit | Rs m | 16,611 | -2,775 | -598.5% | |
Depreciation | Rs m | 11,131 | 691 | 1,610.3% | |
Interest | Rs m | 4,190 | 434 | 965.8% | |
Profit before tax | Rs m | 8,971 | -3,788 | -236.8% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,541 | 237 | 1,073.4% | |
Profit after tax | Rs m | 6,430 | -4,036 | -159.3% | |
Gross profit margin | % | 14.9 | -17.3 | -85.8% | |
Effective tax rate | % | 28.3 | -6.2 | -453.3% | |
Net profit margin | % | 5.8 | -25.2 | -22.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 123,340 | 11,730 | 1,051.5% | |
Current liabilities | Rs m | 85,107 | 6,600 | 1,289.5% | |
Net working cap to sales | % | 34.2 | 32.0 | 106.8% | |
Current ratio | x | 1.4 | 1.8 | 81.5% | |
Inventory Days | Days | 129 | 111 | 116.3% | |
Debtors Days | Days | 117 | 124 | 94.2% | |
Net fixed assets | Rs m | 394,078 | 6,838 | 5,763.4% | |
Share capital | Rs m | 6,003 | 74 | 8,072.9% | |
Net worth | Rs m | 175,929 | 12,571 | 1,399.5% | |
Long term debt | Rs m | 152,905 | 4,418 | 3,461.3% | |
Total assets | Rs m | 517,418 | 23,747 | 2,178.9% | |
Interest coverage | x | 3.1 | -7.7 | -40.6% | |
Debt to equity ratio | x | 0.9 | 0.4 | 247.3% | |
Sales to assets ratio | x | 0.2 | 0.7 | 32.0% | |
Return on assets | % | 2.1 | -15.2 | -13.5% | |
Return on equity | % | 3.7 | -32.1 | -11.4% | |
Return on capital | % | 4.0 | -19.8 | -20.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,525 | 1,367 | 1,355.1% | |
From Investments | Rs m | -142,818 | -420 | 34,023.7% | |
From Financial Activity | Rs m | 130,487 | 4,009 | 3,254.6% | |
Net Cashflow | Rs m | 6,411 | 4,957 | 129.3% |
Compare BIOCON With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare BIOCON With: CIPLA AAYUSH FOOD & HERBS SUPRIYA LIFESCIENCE BAFNA PHARMA FDC
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.